Literature DB >> 23315239

Management of genetic syndromes predisposing to gynecologic cancers.

Susan Miesfeldt1, Amanda Lamb, Christine Duarte.   

Abstract

Women with personal and family histories consistent with gynecologic cancer-associated hereditary cancer susceptibility disorders should be referred for genetic risk assessment and counseling. Genetic counseling facilitates informed medical decision making regarding genetic testing, screening, and treatment, including chemoprevention and risk-reducing surgery. Because of limitations of ovarian cancer screening, hereditary breast and ovarian cancer-affected women are offered risk-reducing bilateral salpingo-oophorectomy (BSO) between ages 35 and 40 years, or when childbearing is complete. Women with documented Lynch syndrome, associated with mutations in mismatch repair genes, should be screened at a young age and provided prevention options, including consideration of risk-reducing total abdominal hysterectomy and BSO, as well as intensive gastrointestinal screening. Clinicians caring for high-risk women must consider the potential adverse ethical, legal, and social issues associated with hereditary cancer risk assessment and testing. Additionally, at-risk family members should be alerted to their cancer risks, as well as the availability of risk assessment, counseling, and treatment services.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23315239     DOI: 10.1007/s11864-012-0215-3

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  79 in total

1.  "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Authors:  David S P Tan; Christian Rothermundt; Karen Thomas; Elizabeth Bancroft; Rosalind Eeles; Susan Shanley; Audrey Ardern-Jones; Andrew Norman; Stanley B Kaye; Martin E Gore
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

Review 2.  Assessing women at high risk of breast cancer: a review of risk assessment models.

Authors:  Eitan Amir; Orit C Freedman; Bostjan Seruga; D Gareth Evans
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

3.  Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.

Authors:  Roger L Milne; Julia A Knight; Esther M John; Gillian S Dite; Ronald Balbuena; Argyrios Ziogas; Irene L Andrulis; Dee W West; Frederick P Li; Melissa C Southey; Graham G Giles; Margaret R E McCredie; John L Hopper; Alice S Whittemore
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

4.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

Review 5.  Application of breast cancer risk prediction models in clinical practice.

Authors:  Susan M Domchek; Andrea Eisen; Kathleen Calzone; Jill Stopfer; Anne Blackwood; Barbara L Weber
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

Review 6.  Cancer susceptibility and the functions of BRCA1 and BRCA2.

Authors:  Ashok R Venkitaraman
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

Review 7.  Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.

Authors:  Ellen Warner; Hans Messersmith; Petrina Causer; Andrea Eisen; Rene Shumak; Donald Plewes
Journal:  Ann Intern Med       Date:  2008-05-06       Impact factor: 25.391

8.  Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.

Authors:  Iris van Oostrom; Hanne Meijers-Heijboer; Litanja N Lodder; Hugo J Duivenvoorden; Arthur R van Gool; Caroline Seynaeve; Conny A van der Meer; Jan G M Klijn; Bert N van Geel; Curt W Burger; Juriy W Wladimiroff; Aad Tibben
Journal:  J Clin Oncol       Date:  2003-10-15       Impact factor: 44.544

9.  Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

Authors:  Angela Chetrit; Galit Hirsh-Yechezkel; Yehuda Ben-David; Flora Lubin; Eitan Friedman; Siegal Sadetzki
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

10.  No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.

Authors:  B B J Hermsen; R I Olivier; R H M Verheijen; M van Beurden; J A de Hullu; L F Massuger; C W Burger; C T Brekelmans; M J Mourits; G H de Bock; K N Gaarenstroom; H H van Boven; T M Mooij; M A Rookus
Journal:  Br J Cancer       Date:  2007-04-10       Impact factor: 7.640

View more
  4 in total

1.  Inherited Mutations in Women With Ovarian Carcinoma.

Authors:  Barbara M Norquist; Maria I Harrell; Mark F Brady; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Sarah S Bernards; Silvia Casadei; Qian Yi; Robert A Burger; John K Chan; Susan A Davidson; Robert S Mannel; Paul A DiSilvestro; Heather A Lankes; Nilsa C Ramirez; Mary Claire King; Elizabeth M Swisher; Michael J Birrer
Journal:  JAMA Oncol       Date:  2016-04       Impact factor: 31.777

2.  Reproductive Endocrinologists' Utilization of Genetic Counselors for Oncofertility and Preimplantation Genetic Diagnosis (PGD) Treatment of BRCA1/2 Mutation Carriers.

Authors:  Allison L Goetsch; Catherine Wicklund; Marla L Clayman; Teresa K Woodruff
Journal:  J Genet Couns       Date:  2015-11-14       Impact factor: 2.537

Review 3.  Genetics of endometrial cancer.

Authors:  Ayelet Shai; Yakir Segev; Steven A Narod
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

4.  Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2.

Authors:  Kyung Jin Eoh; Ji Eun Kim; Hyung Seok Park; Seung-Tae Lee; Ji Soo Park; Jung Woo Han; Jung-Yun Lee; Sunghoon Kim; Sang Wun Kim; Jae Hoon Kim; Young Tae Kim; Eun Ji Nam
Journal:  Cancer Res Treat       Date:  2017-09-27       Impact factor: 4.679

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.